ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Biomimetic Cell Membrane-Coated MOFs System for Targeted Cancer Therapy.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Paclitaxel Nanomedicines: Molecular Mechanisms of Drug Resistance, Tumor Microenvironment-Responsive Delivery, and Translational Challenges.International journal of molecular sciences · 2026Review
- Cell-derived vesicle-modified biomaterials for tissue repair and regeneration.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The integration of metal-organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine. In this review, we systematically summarized recent advances in cell membrane-camouflaged MOF as drug delivery systems, focusing on their unique advantages in tumor targeting, immune evasion, and biocompatibility. By emulating the characteristics of natural cells, these biomimetic systems demonstrate enhanced circulation time, increased accumulation within tumors, and decreased uptake by macrophages. A critical analysis was conducted on a variety of membrane sources, including cancer cells, red blood cells, and macrophages. The analysis focused on the functionalities of these sources in tumor homing and immune modulation. The following design strategies are of particular interest: hybrid membrane engineering and stimuli-responsive drug release mechanisms. This field demonstrates considerable potential for combination therapies integrating chemotherapy, immunotherapy, and photothermal modalities. In the future, the development of new drugs should prioritize intelligent drug release systems and personalized treatment through advanced biomaterial engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.